- Trial Phase
- Phase 2
- Time to Market
- Unknown — leronlimab is in Phase 2 and has no FDA breakthrough or fast track designations publicly noted. If the CLOVER data matures positively, Phase 3 could potentially begin in 2027-2028, meaning an approval (if successful) would be several years away at minimum.
- Why 5/10
- The next hard dated catalyst is the ASCO GI conference (Jan 21-23, 2027) where updated Phase 2 CLOVER data (ORR, PFS, OS) will be presented. This is a data readout, not a regulatory binary. Leronlimab is the sole pipeline asset for CytoDyn, so concentration is high. However, Phase 2 data presentations rarely drive the kind of definitive share-price move that a PDUFA or Phase 3 topline would. There is no FDA filing, no PDUFA date, and no pivotal trial readout scheduled in the next 12 months, capping the impact score at 5.
Watch for CLOVER data updates at ESMO (Oct 23-27, 2026) and ASCO GI (Jan 21-23, 2027) for ORR, PFS, and OS maturation. The ctDNA signal vs. real-world SOC is early and intriguing but requires confirmation. Monitor for any FDA meeting outcomes (planned 2H 2026-1H 2027) and potential partnership or financing announcements. The massive short interest (~36M shares, 11.5 days to cover) creates the potential for a squeeze on positive data, but OTC trading and heavy dilution risk cap upside.
Price Chart
Executive Summary
CytoDyn (CYDY) is a micro-cap OTC biotech entirely focused on leronlimab, an investigational CCR5-targeting monoclonal antibody. Originally developed for HIV under the code PRO 140, the company pivoted to oncology and posted promising but very preliminary Phase 2 ctDNA data from its CLOVER study in metastatic colorectal cancer (mCRC) in October 2026, showing an 86% median ctDNA decline at week 2 (n=28). Leronlimab has no FDA approvals and the company carries a heavy overhang of ~36.3M shares short (11.5 days to cover). The stock trades at $0.26 with a modest $33.7M in cash raised through two 2026 financings. Near-term catalysts are data presentations at ESMO (late Oct 2026) and ASCO GI (Jan 2027), but these are Phase 2 interim data updates — not pivotal readouts or regulatory filings. The stock is a high-risk, binary play on early oncology data from a single-asset company with a history of setbacks and limited institutional coverage.
How It Works
Leronlimab is a lab-made antibody that blocks a receptor on immune cells called CCR5. CCR5 acts like a doorway — HIV uses it to enter cells, and some cancers use it to hide from the immune system. By blocking CCR5, leronlimab aims to keep the immune system's cancer-killing T-cells active against tumors. It is given as a weekly subcutaneous (under-the-skin) injection.
Trial Status
The lead program is the Phase 2 CLOVER study (N=65) in metastatic colorectal cancer (mCRC). Preliminary data released in October 2026 showed a median 86% decline in circulating tumor DNA (ctDNA) at week 2 across 28 evaluable patients, with 74.5% of 51 evaluable patients showing tumor shrinkage or stable disease at Week 8. Three patients were referred for curative-intent surgery. No serious adverse events related to leronlimab were reported. The study is ongoing with ~34% of subjects still on treatment as of September 2026. The company also has early-stage efforts in HIV (long-acting formulation) and other oncology indications.
The Two-Sided Case
Upcoming Catalysts
- CLOVER Phase 2 data at ESMO (Oct 23-27, 2026) — more mature ORR, PFS, and OS data expected
- CLOVER Phase 2 data at ASCO GI (Jan 21-23, 2027) — durability and response rate update
- FDA communication/meeting planned for 2H 2026 to 1H 2027 to discuss regulatory path
- Potential partnership or licensing deal for leronlimab in oncology
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CytoDyn Inc. DEFA14A CYDY ·Originating report